FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316081671> ?p ?o ?g. }

• W4316081671 endingPage "e762" @default.
• W4316081671 startingPage "e762" @default.
• W4316081671 abstract "Introduction: Despite the advance in therapeutic options for the treatment of Crohn’s disease (CD), there remains a significant portion of patients with ongoing disease activity. Few studies have characterized medically refractory CD. Identifying patients that are true primary non responders to multiple therapies may reveal novel mechanisms on which future therapies can be built. Here we describe the clinical characteristics of CD patients that are primary non-responders to all 3 FDA approved classes of biologics from a tertiary center. Methods: Two datasets were used to optimize criteria for primary medical non-responders: a randomly selected cross sectional dataset of 783 patients and a dataset of 42 patients screened for a clinical trial that permitted failure of 3 biologics. Internal review of the datasets and iterative optimization of primary non-response criteria settled on the following factors to define primary medication non-response (1) demonstrated endoscopic disease activity, (2) trial of therapy > 6 months, and (3) no record of adverse event. Results: Of 806 patients reviewed, 19 met criteria for primary non response across 3 biologic classes. Mean age at diagnosis was 24.7 and 53% were male. Disease distribution: 13 (68%) patients with ileocolitis, 4 (21%) patients with colitis, & 2 (11%) patients with ileitis/jejunitis. 2 (11%) patients had upper tract involvement. Regarding phenotype, 5 (31.2%) patients had inflammatory (B1), 5 (31.2%) had fibrostenotic (B2), & 9 (56.3%) patients had penetrating (B3) disease. 3 (15.7%) patients had perianal disease. 12 (63%) patients had prior CD surgery. The refractory patients had more upper tract disease and B3 disease compared to controls. 18 patients received an anti-TNF agent as the 1st biologic class & 1 received an anti-a4b7 integrin. 2nd class: 10 received anti-a4b7 integrin, 8 received an anti-IL12/23, & 1 received anti-a4b1 integrin. 3rd class: anti-a4b7 integrin in 10, anti-IL12/23 in 8 and anti-TNF in 1. Strategies employed after biologic failure were trial referral (16), recycling class (10), med optimization (5), surgery (2), off label meds (2) & combo biologics (1). Conclusion: This retrospective review demonstrates there is a subset of highly medically refractory CD patients that are primary non-responders to multiple biologics. Common clinical characteristics don’t allow the identification of these patients, suggesting the need for molecular phenotyping in order to identify rational rescue therapies for this unique subset of patients.Figure 1.: Sequence of class selection in group of multiple biologic refractory patients Table 1. - Comparison of clinical characteristics between refractory group (primary non-response to 3+ classes of biologics) vs non-refractory patients. (Crohn's Disease = CD) Multiple Biologic Refractory Patients (n = 19) Non-Refractory Patients (n = 787) P value Mean age at Dx (yrs) 24.7 26.17534943 0.999 Male 10 (52.6%) 427 (54.2%) 0.883 Female 9 (47.4%) 360 (45.7%) 0.883 Ileocolitis Distribution 13 (68.4%) 413 (52.4%) 0.278 Colitis Distribution 4 (21.1%) 173 (22.0%) 0.278 leal Distribution 2 (10.5%) 201 (25.5%) 0.278 Upper GI CD 2 (10.5%) 9 (1.14%) 0.0005 B1 (Non-stricturing, Non-penetrating) 5 (26.3%) 455 (57.8%) --- B2 (Stricturing) 5 (26.3%) 225 (28.6%) --- B3 (Penetrating) 9 (47.4%) 106 (13.5%) 0.00002 Perianal Disease 3 (15.8%) 69 (8.77%) 0.289 Prior CD Surgery 11 (58.0%) 340 (43.2%) 0.201" @default.
• W4316081671 created "2023-01-14" @default.
• W4316081671 creator A5015470174 @default.
• W4316081671 creator A5028291081 @default.
• W4316081671 creator A5033087694 @default.
• W4316081671 creator A5040471749 @default.
• W4316081671 date "2022-10-01" @default.
• W4316081671 modified "2023-10-16" @default.
• W4316081671 title "S1052 Characterization of Crohn’s Patients That Are Multiple Primary Non-Responders to Biologic Therapies" @default.
• W4316081671 doi "https://doi.org/10.14309/01.ajg.0000860848.89740.90" @default.
• W4316081671 hasPublicationYear "2022" @default.
• W4316081671 type Work @default.
• W4316081671 citedByCount "0" @default.
• W4316081671 crossrefType "journal-article" @default.
• W4316081671 hasAuthorship W4316081671A5015470174 @default.
• W4316081671 hasAuthorship W4316081671A5028291081 @default.
• W4316081671 hasAuthorship W4316081671A5033087694 @default.
• W4316081671 hasAuthorship W4316081671A5040471749 @default.
• W4316081671 hasBestOaLocation W43160816711 @default.
• W4316081671 hasConcept C121332964 @default.
• W4316081671 hasConcept C126322002 @default.
• W4316081671 hasConcept C142424586 @default.
• W4316081671 hasConcept C197934379 @default.
• W4316081671 hasConcept C2778260677 @default.
• W4316081671 hasConcept C2779134260 @default.
• W4316081671 hasConcept C2779280984 @default.
• W4316081671 hasConcept C2780132546 @default.
• W4316081671 hasConcept C535046627 @default.
• W4316081671 hasConcept C71924100 @default.
• W4316081671 hasConcept C87355193 @default.
• W4316081671 hasConcept C90924648 @default.
• W4316081671 hasConceptScore W4316081671C121332964 @default.
• W4316081671 hasConceptScore W4316081671C126322002 @default.
• W4316081671 hasConceptScore W4316081671C142424586 @default.
• W4316081671 hasConceptScore W4316081671C197934379 @default.
• W4316081671 hasConceptScore W4316081671C2778260677 @default.
• W4316081671 hasConceptScore W4316081671C2779134260 @default.
• W4316081671 hasConceptScore W4316081671C2779280984 @default.
• W4316081671 hasConceptScore W4316081671C2780132546 @default.
• W4316081671 hasConceptScore W4316081671C535046627 @default.
• W4316081671 hasConceptScore W4316081671C71924100 @default.
• W4316081671 hasConceptScore W4316081671C87355193 @default.
• W4316081671 hasConceptScore W4316081671C90924648 @default.
• W4316081671 hasIssue "10S" @default.
• W4316081671 hasLocation W43160816711 @default.
• W4316081671 hasLocation W43160816712 @default.
• W4316081671 hasOpenAccess W4316081671 @default.
• W4316081671 hasPrimaryLocation W43160816711 @default.
• W4316081671 hasRelatedWork W1543168456 @default.
• W4316081671 hasRelatedWork W1588288904 @default.
• W4316081671 hasRelatedWork W1989121959 @default.
• W4316081671 hasRelatedWork W2085326056 @default.
• W4316081671 hasRelatedWork W2317479536 @default.
• W4316081671 hasRelatedWork W2755604283 @default.
• W4316081671 hasRelatedWork W2810268285 @default.
• W4316081671 hasRelatedWork W2944240382 @default.
• W4316081671 hasRelatedWork W3044759252 @default.
• W4316081671 hasRelatedWork W4293512766 @default.
• W4316081671 hasVolume "117" @default.
• W4316081671 isParatext "false" @default.
• W4316081671 isRetracted "false" @default.
• W4316081671 workType "article" @default.